A Trenton, N.J., federal judge has denied GlaxoSmithKline’s bid to toss out a $106 million verdict against it for breaching a contract granting Mylan Pharmaceuticals exclusive rights to make a generic version of the antidepressant Paxil CR.
Ample evidence supported the jury’s finding that GSK breached its contract with Mylan concerning sales of Paxil, and nothing about the verdict presents a miscarriage of justice, U.S. District Judge Joel Pisano ruled July 16 in denying a new trial or judgment as a matter of law in Mylan v. SmithKline Beecham, 10-cv-4809. Similarly, in denying GSK’s bid for remittitur, Pisano rejected its claims that the damages calculation failed to account for short supplies of Mylan’s version of the drug.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
